Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611229 · ClinicalTrials.gov registry record
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,975
- Enrollment target
NCT05611229 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,975 participants.
The verdict
NCT05611229 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,975 participants
- Enrollment target
Study Summary
This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- COMBINATION_PRODUCT Dabrafenib+Trametinib
- COMBINATION_PRODUCT Ipilimumab+Nivolumab
- COMBINATION_PRODUCT Vemurafenib+Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,975 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-12-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05611229
The ClinicalTrials.gov registry entry for NCT05611229 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05611229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05611229 about?
NCT05611229 is a clinical study titled "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden". This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.
What is the current status of trial NCT05611229?
This trial is currently completed. The enrollment target is 1,975 participants. The study started on 2020-06-16. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT05611229?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Dabrafenib+Trametinib (COMBINATION_PRODUCT), Ipilimumab+Nivolumab (COMBINATION_PRODUCT), Vemurafenib+Cobimetinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05611229?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.